OBJECTIVE: After treatment with refractive correction and patching, some patients have residual amblyopia resulting from strabismus or anisometropia. We conducted a clinical trial to evaluate the effectiveness of increasing prescribed daily patching from 2 to 6 hours in children with stable residual amblyopia. DESIGN: Prospective, randomized, multicenter clinical trial. PARTICIPANTS: A total of 169 children aged 3 to <8 years (mean, 5.9 years) with stable residual amblyopia (20/32-20/160) after 2 hours of daily patching for at least 12 weeks. INTERVENTION: Random assignment to continue 2 hours of daily patching or increase patching time to an average of 6 hours/day. MAIN OUTCOME MEASURES: Best-corrected visual acuity (VA) in the amblyopic eye after 10 weeks. RESULTS: Baseline VA was 0.44 logarithm of the minimum angle of resolution (logMAR) (20/50(-2)). Ten weeks after randomization, amblyopic eye VA had improved an average of 1.2 lines in the 6-hour group and 0.5 line in the 2-hour group (difference in mean VA adjusted for acuity at randomization = 0.6 line; 95% confidence interval, 0.3-1.0; P = 0.002). Improvement of 2 or more lines occurred in 40% of participants patched for 6 hours versus 18% of those who continued to patch for 2 hours (P = 0.003). CONCLUSIONS: When amblyopic eye VA stops improving with 2 hours of daily patching, increasing the daily patching dosage to 6 hours results in more improvement in VA after 10 weeks compared with continuing 2 hours daily.
RCT Entities:
OBJECTIVE: After treatment with refractive correction and patching, some patients have residual amblyopia resulting from strabismus or anisometropia. We conducted a clinical trial to evaluate the effectiveness of increasing prescribed daily patching from 2 to 6 hours in children with stable residual amblyopia. DESIGN: Prospective, randomized, multicenter clinical trial. PARTICIPANTS: A total of 169 children aged 3 to <8 years (mean, 5.9 years) with stable residual amblyopia (20/32-20/160) after 2 hours of daily patching for at least 12 weeks. INTERVENTION: Random assignment to continue 2 hours of daily patching or increase patching time to an average of 6 hours/day. MAIN OUTCOME MEASURES: Best-corrected visual acuity (VA) in the amblyopic eye after 10 weeks. RESULTS: Baseline VA was 0.44 logarithm of the minimum angle of resolution (logMAR) (20/50(-2)). Ten weeks after randomization, amblyopic eye VA had improved an average of 1.2 lines in the 6-hour group and 0.5 line in the 2-hour group (difference in mean VA adjusted for acuity at randomization = 0.6 line; 95% confidence interval, 0.3-1.0; P = 0.002). Improvement of 2 or more lines occurred in 40% of participants patched for 6 hours versus 18% of those who continued to patch for 2 hours (P = 0.003). CONCLUSIONS: When amblyopic eye VA stops improving with 2 hours of daily patching, increasing the daily patching dosage to 6 hours results in more improvement in VA after 10 weeks compared with continuing 2 hours daily.
Authors: P S Moke; A H Turpin; R W Beck; J M Holmes; M X Repka; E E Birch; R W Hertle; R T Kraker; J M Miller; C A Johnson Journal: Am J Ophthalmol Date: 2001-12 Impact factor: 5.258
Authors: J M Holmes; R W Beck; M X Repka; D A Leske; R T Kraker; R C Blair; P S Moke; E E Birch; R A Saunders; R W Hertle; G E Quinn; K A Simons; J M Miller Journal: Arch Ophthalmol Date: 2001-09
Authors: Susan A Cotter; Nicole C Foster; Jonathan M Holmes; B Michele Melia; David K Wallace; Michael X Repka; Susanna M Tamkins; Raymond T Kraker; Roy W Beck; Darren L Hoover; Eric R Crouch; Aaron M Miller; Christie L Morse; Donny W Suh Journal: Ophthalmology Date: 2011-09-29 Impact factor: 12.079
Authors: David K Wallace; Allison R Edwards; Susan A Cotter; Roy W Beck; Robert W Arnold; William F Astle; Carmen N Barnhardt; Eileen E Birch; Sean P Donahue; Donald F Everett; Joost Felius; Jonathan M Holmes; Raymond T Kraker; Michele Melia; Michael X Repka; Nicholas A Sala; David I Silbert; Katherine K Weise Journal: Ophthalmology Date: 2006-06 Impact factor: 12.079
Authors: Susan A Cotter; Allison R Edwards; David K Wallace; Roy W Beck; Robert W Arnold; William F Astle; Carmen N Barnhardt; Eileen E Birch; Sean P Donahue; Donald F Everett; Joost Felius; Jonathan M Holmes; Raymond T Kraker; Michele Melia; Michael X Repka; Nicholas A Sala; David I Silbert; Katherine K Weise Journal: Ophthalmology Date: 2006-06 Impact factor: 12.079
Authors: Jonathan M Holmes; Roy W Beck; Raymond T Kraker; William F Astle; Eileen E Birch; Stephen R Cole; Susan A Cotter; Sean Donahue; Donald F Everett; Richard W Hertle; Ronald V Keech; Evelyn Paysse; Graham F Quinn; Michael X Repka; Mitchell M Scheiman Journal: J AAPOS Date: 2004-10 Impact factor: 1.220
Authors: Michael X Repka; Roy W Beck; Jonathan M Holmes; Eileen E Birch; Danielle L Chandler; Susan A Cotter; Richard W Hertle; Raymond T Kraker; Pamela S Moke; Graham E Quinn; Mitchell M Scheiman Journal: Arch Ophthalmol Date: 2003-05
Authors: David K Wallace; Elizabeth L Lazar; Earl R Crouch; Darren L Hoover; Raymond T Kraker; Susanna M Tamkins Journal: JAMA Ophthalmol Date: 2015-05 Impact factor: 7.389